TiGenix is a biomedical company operating at the cutting edge of regenerative medicine. Its core mission is to provide a comprehensive solution for damaged and osteoarthritic joints through the combination of innovative cellular therapies and locally delivered therapeutics. We are constantly on the lookout to strengthen our team. If you are interested and believe you can contribute to our success, don't hesitate to contact us at careers@tigenix.com.
The Company's first product, ChondroCelect, is an improved ACI product, the first to incorporate identity characterization based on in vivo biological function. Designed to guarantee formation of stable hyaline cartilage in vivo, ChondroCelect aims at true functional repair of the demaged joint surface.
Rebekka Declercq,
TiGenix,
Technologielaan 3,
3001 Leuven.
